Compare

Natural Alternatives International Inc vs Cronos Group Inc. vs Niagen Bioscience, Inc. vs Marimed Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearNatural Alternatives International Inc
NAII
Cronos Group Inc.
CRON
Niagen Bioscience, Inc.
NAGE
Marimed Inc.
MRMD
Year ended2026-06-302025-12-312025-12-312025-12-31
Revenue$142.51M$146.59M$129.42M$159.83M
Revenue growth (YoY)+9.7%+24.6%+29.9%+1.3%
Gross margin6.3%42.8%64.3%36.2%
Operating margin-13.2%-11.9%12.6%-1.8%
Net margin-14.5%-6.4%13.4%-9.1%
Net income-$20.70M-$9.45M$17.38M-$14.48M
EPS (Diluted)-$3.43-$0.02$0.20-$0.04
Operating cash flow-$8.92M$25.87M$13.50M$7.70M
Free cash flow-$12.62M$149.0Kn/a$6.53M
Cash & equivalents$7.39M$791.79Mn/an/a
Total assets$126.45M$1.20B$106.41M$202.56M
Total liabilities$76.49M$54.18M$29.87M$137.83M
Shareholders' equity$49.96M$1.14B$76.53M$50.01M
Return on year-end equity-41.4%-0.8%22.7%-29.0%
Shares outstanding6.27M381.59M79.71M396.91M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearNatural Alternatives International IncCronos Group Inc.Niagen Bioscience, Inc.Marimed Inc.
Latest$142.51M
Ended 2026-06-30
$146.59M
Ended 2025-12-31
$129.42M
Ended 2025-12-31
$159.83M
Ended 2025-12-31
1 year earlier$129.86M
Ended 2025-06-30
$117.61M
Ended 2024-12-31
$99.60M
Ended 2024-12-31
$157.71M
Ended 2024-12-31
2 years earlier$113.80M
Ended 2024-06-30
$87.24M
Ended 2023-12-31
$83.57M
Ended 2023-12-31
$148.60M
Ended 2023-12-31
3 years earlier$154.01M
Ended 2023-06-30
$86.75M
Ended 2022-12-31
$72.05M
Ended 2022-12-31
$134.01M
Ended 2022-12-31
4 years earlier$170.97M
Ended 2022-06-30
$64.56M
Ended 2021-12-31
$67.45M
Ended 2021-12-31
$121.46M
Ended 2021-12-31